Open AccessPeroxisome proliferator-activated receptor γ ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats
Author(s) -
Yaming Guo,
Xi-sheng Leng,
Tao Li,
Jingming Zhao,
Xiaoqin Lin
Publication year - 2004
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v10.i23.3419
Subject(s) - peroxisome proliferator activated receptor , carcinogenesis , pioglitazone , troglitazone , chemistry , endocrinology , medicine , peroxisome , carcinogen , peroxisome proliferator , receptor , liver cancer , glutathione , peroxisome proliferator activated receptor alpha , cancer research , cancer , biology , biochemistry , transcription factor , nuclear receptor , enzyme , diabetes mellitus , type 2 diabetes , gene
Peroxisome proliferator-activated receptor gamma (PPARgamma) is known to regulate growth arrest and terminal differentiation of adipocytes and is used clinically as a new class of antidiabetic drugs. Recently, several studies have reported that treatment of cancer cells with PPARgamma ligands could induce cell differentiation and apoptosis, suggesting a potential application as chemopreventive agents against carcinogenesis. In the present study, 3 different kinds of PPARgamma ligands were subjected to the experiments to confirm their suppressive effects on liver carcinogenesis.